Compare Equitable Holdings Inc. Common Stock (EQH) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equitable Holdings Inc. Common Stock vs Illumina, Inc. — how do they compare? Equitable Holdings Inc. Common Stock trades at $52.77 (market cap $14.42B), while Illumina, Inc. trades at $271.46 (market cap $41.04B). The key difference: Illumina, Inc. is far larger — about 2.8× Equitable Holdings Inc. Common Stock's market cap, and Equitable Holdings Inc. Common Stock pays a 2.16% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equitable Holdings Inc. Common Stock for 0 Days and Illumina, Inc. for 84 Days on average.
| EQH | ILMN | |
|---|---|---|
Market Cap | $14.42B | $41.04B |
Volume | 2,107,298 | 2,120,523 |
Sector | Financials | Health |
52-Week High | $54.50 | $293.69 |
52-Week Low | $35.34 | $93.00 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $5.48B | $42.39B |
Dividend Yield | 2.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equitable Holdings (EQH) trades at $53.12, down 0.75% on the day, with strong analyst support (95% buy ratings) and a $64.71 consensus price target suggesting 22% upside. Recent quarterly earnings have consistently beaten expectations, though the company reported a net loss of $1.38B for 2025. The planned merger with Corebridge and expansion into fee-based businesses are key growth drivers, while high debt-to-asset ratio of 2.07 presents financial risk.
EQH shows mixed fundamentals with positive earnings momentum but negative profitability metrics. The stock offers significant upside potential based on analyst targets, supported by strategic initiatives and dividend appeal. Key risks include execution of the Corebridge merger, persistent net losses, and high leverage. Investors should weigh strong analyst conviction against fundamental weaknesses.
Illumina (ILMN) trades at $271.18, down 1.99% but near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Revenue remains stable at $4.3B with impressive profitability metrics including 66.4% gross margin and 18.3% net income margin. Recent news highlights S&P 500 inclusion and AI-driven growth initiatives.
ILMN presents a mixed outlook with strong fundamentals and technical momentum offset by premium valuations (P/E 50.6). The primary opportunity lies in genomic sequencing leadership and AI integration, while risks include valuation sensitivity and competitive pressures. Analyst consensus leans bullish with 54% buy ratings but a $241 price target suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equitable Holdings Inc. Common Stock
Equitable Holdings, Inc. is a financial services holding company operating through Equitable, AllianceBernstein, and Equitable Advisors. It provides retirement and protection products, asset and wealth management services, and financial planning through a network of registered financial professionals.
Read more on EQH →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
